Reid Huber is a partner at Third Rock Ventures, having joined the firm in 2018 to focus on the formation, development and strategy of the firm’s portfolio companies. Reid has over 20 years of experience in biopharma R&D leadership, ranging from early drug discovery to late-stage drug development, and currently serves on the board of Asher Bio, CARGO Therapeutics, MOMA Therapeutics, Tango Therapeutics, Terremoto Therapeutics, and insitro.

Before joining Third Rock, Reid spent over 16 years at Incyte, where he was a member of the founding scientific team. During his time at Incyte, Reid served in multiple senior leadership roles across R&D including senior vice president of discovery biology and executive vice president, chief scientific officer. He has worked across many therapeutic areas, gaining extensive knowledge of pharmaceutical research and clinical development. Prior to that, Reid held positions of increasing responsibility at DuPont Pharmaceuticals and Bristol-Myers Squibb.

Reid earned his doctorate in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes of Health.